{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-020513","form_type":"8-K","ticker":"SINT","cik":"0001269026","company_name":"Sintx Technologies, Inc.","filed_at":"2025-07-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.553570+00:00","generated_at":"2026-05-18T04:09:34.782657+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SINTX submits FDA 510(k) for silicon nitride foot/ankle implants, entering $750M market","bullets":["Filed 510(k) for silicon nitride osteotomy wedges on July 22, 2025, targeting foot/ankle fusion.","Foot/ankle fusion market valued at $750.5M, projected to reach $1.38B by 2032.","Biomaterial track record: >50,000 spinal implants since 2008; antimicrobial & radiolucent properties.","Implants to be manufactured at SINTX's FDA/ISO facility, distributed as SiNAPTIC Surgical (acquired July 1, 2025).","Expected to drive revenue growth through hospital and ASC adoption with single-use instrumentation."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-020513","json":"https://secwatch.observer/filing/0001641172-25-020513.json","markdown":"https://secwatch.observer/filing/0001641172-25-020513.md","text":"https://secwatch.observer/filing/0001641172-25-020513.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1269026/000164117225020513/0001641172-25-020513-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1269026/000164117225020513/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T04:09:34.782657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001193125-26-251421","ticker":"GENC","company_name":"GENCOR INDUSTRIES INC","filed_at":"2026-06-01T20:09:26+00:00","headline":"Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251421","json":"https://secwatch.observer/filing/0001193125-26-251421.json","markdown":"https://secwatch.observer/filing/0001193125-26-251421.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/d135716d8k.htm"},"side_by_side_evidence":null},{"accession":"0001140361-26-023560","ticker":"NJR","company_name":"NEW JERSEY RESOURCES CORP","filed_at":"2026-06-01T20:03:21+00:00","headline":"NJNG files base rate case seeking $157.6M increase; offers 8.9% winter bill cut","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023560","json":"https://secwatch.observer/filing/0001140361-26-023560.json","markdown":"https://secwatch.observer/filing/0001140361-26-023560.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/356309/000114036126023560/0001140361-26-023560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/356309/000114036126023560/ef20075084_8k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-026519","ticker":"ELTP","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2026-06-01T11:00:24+00:00","headline":"Elite Pharmaceuticals files ANDA for generic anticoagulant; $26B brand market, no generic available","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026519","json":"https://secwatch.observer/filing/0001493152-26-026519.json","markdown":"https://secwatch.observer/filing/0001493152-26-026519.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226026519/0001493152-26-026519-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226026519/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-062935","ticker":"ATNM","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2026-05-29T21:10:41+00:00","headline":"Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062935","json":"https://secwatch.observer/filing/0001213900-26-062935.json","markdown":"https://secwatch.observer/filing/0001213900-26-062935.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-068002","ticker":"REPL","company_name":"Replimune Group, Inc.","filed_at":"2026-05-29T13:56:10+00:00","headline":"Replimune to resubmit RP1 BLA for advanced melanoma; FDA agrees to prioritize review","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068002","json":"https://secwatch.observer/filing/0001104659-26-068002.json","markdown":"https://secwatch.observer/filing/0001104659-26-068002.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926068002/0001104659-26-068002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926068002/tm2615980d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-025629","ticker":"CDT","company_name":"CDT Equity Inc.","filed_at":"2026-05-28T20:30:30+00:00","headline":"CDT Equity receives Nasdaq deficiency letter for late Q1 10-Q filing; has until July 20 to submit plan","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025629","json":"https://secwatch.observer/filing/0001493152-26-025629.json","markdown":"https://secwatch.observer/filing/0001493152-26-025629.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/0001493152-26-025629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001437749-26-018670","ticker":"BCDA","company_name":"BioCardia, Inc.","filed_at":"2026-05-28T12:00:11+00:00","headline":"BioCardia Japan PMDA supports CardiAMP cell therapy submission for HFrEF; submission planned Q4 2026","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-018670","json":"https://secwatch.observer/filing/0001437749-26-018670.json","markdown":"https://secwatch.observer/filing/0001437749-26-018670.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/925741/000143774926018670/0001437749-26-018670-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/925741/000143774926018670/bcda20260528_8k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-025454","ticker":"GWAV","company_name":"Greenwave Technology Solutions, Inc.","filed_at":"2026-05-27T21:25:20+00:00","headline":"Greenwave receives second Nasdaq delinquency notice for late Q1 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025454","json":"https://secwatch.observer/filing/0001493152-26-025454.json","markdown":"https://secwatch.observer/filing/0001493152-26-025454.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589149/000149315226025454/0001493152-26-025454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589149/000149315226025454/form8-k.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}